Drug Profile
Research programme: protein therapeutic - Sanofi/Lipoxen
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation; Lipoxen Technologies
- Developer Sanofi; Xenetic Biosciences
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in USA